Turner JH, et al. Cancer Biother. Radiopharm. (2003) cited as Ref 550 in DOI: 10.1038/s41392-020-0110-5

From Wikibase.slis.ua.edu
Revision as of 15:09, 20 May 2020 by Maintenance script (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Bibliography entry in "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8; DOI: https://doi.org/10.1038/s41392-020-0110-5


Information about this Cited Reference
Title131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital
DOI10.1089/108497803322287583
1st AUTurner JH
2nd AUMartindale AA
3rd AUClaringbold PG
4th AULeahy MF
PubDate2003
JournalCancer Biother. Radiopharm.
Volume18
Page(s)513-524
Cited InTargeting cancer stem cell pathways for cancer therapy (DOI: 10.1038/s41392-020-0110-5)
Retrieved from "http://wikibase.slis.ua.edu/w/index.php?title=Turner_JH,_et_al._Cancer_Biother._Radiopharm._(2003)_cited_as_Ref_550_in_DOI:_10.1038/s41392-020-0110-5&oldid=198453"